{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:55Z","timestamp":1793215135554,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Distinguished Young Scientists in Nanjing","award":["JQX15002"],"award-info":[{"award-number":["JQX15002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ApoE-\/- mice were fed a Western diet for 12\u2009weeks to induce atherosclerosis. On the 7th week, a group of mice were treated with drinking water containing empagliflozin (10\u2009mg\/kg\/day), while another group was given normal water. At the 12th week, the whole aortas of each group were harvested. Oil Red O, HE and Movat staining were performed for atherosclerotic lesion area and size. Mouse serum lipid profiles (total cholesterol [TC], triglyceride [TG], low-density lipoprotein-c [LDL], and high-density lipoprotein-c [HDL]), systemic inflammation levels (IL-1\u03b2, IL-6 and IL-10), renin-angiotensin-aldosterone system (RAAS) components and sympathetic activity (norepinephrine and neuropeptide Y) indicators were measured by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Empagliflozin reduced the atherosclerotic lesion burden (-8.6\u2009%,<jats:italic>P<\/jats:italic>\u2009=\u20090.004) at aortic root in ApoE-\/- mice. In addition, empagliflozin decreased body weight (-3.27\u2009g,<jats:italic>P<\/jats:italic>\u2009=\u20090.002), lipid profiles (TC: [-15.3\u2009mmol\/L,<jats:italic>P<\/jats:italic>\u2009=\u20090.011]; TG: [-2.4\u2009mmol\/L,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001]; LDL: [-2.9\u2009mmol\/L,<jats:italic>P<\/jats:italic>\u2009=\u20090.010]), RAAS (renin [-9.3\u2009ng\/L,<jats:italic>P<\/jats:italic>\u2009=\u20090.047]; aldosterone [-16.7\u2009ng\/L,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001]) and sympathetic activity (norepinephrine [-8.9\u2009ng\/L,<jats:italic>P<\/jats:italic>\u2009=\u20090.019]; neuropeptide Y [-8.8\u2009ng\/L,<jats:italic>P<\/jats:italic>\u2009=\u20090.002]). However, the anti-inflammatory effect of empagliflozin was not significantly evident.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The early atherosclerotic lesion size was less visible in empagliflozin-treated mice. Empagliflozin could decrease lipid profiles and sympathetic activity in atherosclerosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12944-021-01430-y","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T06:15:48Z","timestamp":1610432148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity"],"prefix":"10.1186","volume":"20","author":[{"given":"Yihai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93:397\u2013404.","journal-title":"J Clin Invest"},{"key":"1430_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12020-016-0943-4","volume":"53","author":"RP Monica Reddy","year":"2016","unstructured":"Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine. 2016;53:364\u201372.","journal-title":"Endocrine"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515\u201331.","journal-title":"Endocr Rev"},{"key":"1430_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1430_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, Group CPC. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1430_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/dom.12261","volume":"16","author":"J Dziuba","year":"2014","unstructured":"Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014;16:628\u201335.","journal-title":"Diabetes Obes Metab"},{"key":"1430_CR8","doi-asserted-by":"publisher","first-page":"6305735","DOI":"10.1155\/2016\/6305735","volume":"2016","author":"W Leng","year":"2016","unstructured":"Leng W, Ouyang X, Lei X, Wu M, Chen L, Wu Q, Deng W, Liang Z. The SGLT-2 Inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-\/-) mice. Mediators Inflamm. 2016;2016:6305735.","journal-title":"Mediators Inflamm"},{"key":"1430_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","volume":"17","author":"DM Lee","year":"2018","unstructured":"Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62.","journal-title":"Cardiovasc Diabetol"},{"key":"1430_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou PE, Maratou E, Lambadiari V, et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol. 2017;8:1077.","journal-title":"Front Physiol"},{"key":"1430_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1751-7133.2008.07210.x","volume":"14","author":"H Ooi","year":"2008","unstructured":"Ooi H, Chung W, Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail. 2008;14:31\u20136.","journal-title":"Congest Heart Fail"},{"key":"1430_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","volume":"15","author":"A Garcia-Ropero","year":"2019","unstructured":"Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;15:275\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1430_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/jpet.118.253666","volume":"368","author":"H Oshima","year":"2019","unstructured":"Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368:524\u201334.","journal-title":"J Pharmacol Exp Ther"},{"key":"1430_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/cvr\/cvy295","volume":"115","author":"KL Chin","year":"2019","unstructured":"Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res. 2019;115:266\u201376.","journal-title":"Cardiovasc Res"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146-603.","journal-title":"Circulation"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3324\/haematol.2018.192898","volume":"104","author":"A Al-Sharea","year":"2019","unstructured":"Al-Sharea A, Lee MKS, Whillas A, Michell DL, Shihata WA, Nicholls AJ, Cooney OD, Kraakman MJ, Veiga CB, Jefferis AM, et al. Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis. Haematologica. 2019;104:456\u201367.","journal-title":"Haematologica"},{"key":"1430_CR17","first-page":"5362","volume":"12","author":"H Chen","year":"2020","unstructured":"Chen H, Wang R, Xu F, Zang T, Ji M, Yin J, Chen J, Shen L, Ge J. Renal denervation mitigates atherosclerosis in ApoE-\/- mice via the suppression of inflammation. Am J Transl Res. 2020;12:5362\u201380.","journal-title":"Am J Transl Res"},{"key":"1430_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2174\/138161212799436467","volume":"18","author":"A Durante","year":"2012","unstructured":"Durante A, Peretto G, Laricchia A, Ancona F, Spartera M, Mangieri A, Cianflone D. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 2012;18:981\u20131004.","journal-title":"Curr Pharm Des"},{"key":"1430_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11886-012-0275-9","volume":"14","author":"MM Patarroyo Aponte","year":"2012","unstructured":"Patarroyo Aponte MM, Francis GS. Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention. Curr Cardiol Rep. 2012;14:433\u201342.","journal-title":"Curr Cardiol Rep"},{"key":"1430_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, Park KS, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet. Diabetologia. 2017;60:364\u201376.","journal-title":"Diabetologia"},{"key":"1430_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","volume":"271","author":"A Al-Sharea","year":"2018","unstructured":"Al-Sharea A, Murphy AJ, Huggins LA, Hu Y, Goldberg IJ, Nagareddy PR. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-\/-) type 1 diabetic mice. Atherosclerosis. 2018;271:166\u201376.","journal-title":"Atherosclerosis"},{"key":"1430_CR22","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1038\/s41598-019-54224-9","volume":"9","author":"J Pennig","year":"2019","unstructured":"Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Funer L, Hardtner C, Stachon P, Wolf D, Hilgendorf I, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep. 2019;9:17937.","journal-title":"Sci Rep"},{"key":"1430_CR23","doi-asserted-by":"crossref","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13:e006277.","journal-title":"Circ Heart Fail"},{"key":"1430_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu Y, Liu X, Xu L, Li X, Yu X, et al. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci (Lond). 2019;133:1705\u201320.","journal-title":"Clin Sci (Lond)"},{"key":"1430_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol"},{"key":"1430_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1479164115616901","volume":"13","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119\u201326.","journal-title":"Diab Vasc Dis Res"},{"key":"1430_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14740\/jocmr3650","volume":"11","author":"H Kakuda","year":"2019","unstructured":"Kakuda H, Kobayashi J, Sakurai M, Takekoshi N. Residual effect of sodium glucose cotransporter 2 inhibitor, tofogliflozin, on body weight after washout in Japanese men with type 2 diabetes. J Clin Med Res. 2019;11:35\u201341.","journal-title":"J Clin Med Res"},{"key":"1430_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/14656566.2017.1363888","volume":"18","author":"A Ohta","year":"2017","unstructured":"Ohta A, Kato H, Ishii S, Sasaki Y, Nakamura Y, Nakagawa T, Nagai Y, Tanaka Y. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother. 2017;18:1433\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"1430_CR29","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1161\/ATVBAHA.119.312870","volume":"39","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Hu J, Wu Y, Luo H, Meng W, Xiao B, Xiao X, Zhou Z, Liu F. Rheb (Ras Homolog Enriched in Brain 1) deficiency in mature macrophages prevents atherosclerosis by repressing macrophage proliferation, inflammation, and lipid uptake. Arterioscler Thromb Vasc Biol. 2019;39:1787\u2013801.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1430_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.116.026644","volume":"136","author":"AC Finney","year":"2017","unstructured":"Finney AC, Funk SD, Green JM, Yurdagul A Jr, Rana MA, Pistorius R, Henry M, Yurochko A, Pattillo CB, Traylor JG, et al. EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis. Circulation. 2017;136:566\u201382.","journal-title":"Circulation"},{"key":"1430_CR31","doi-asserted-by":"publisher","first-page":"13151","DOI":"10.1038\/ncomms13151","volume":"7","author":"D Zysset","year":"2016","unstructured":"Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun. 2016;7:13151.","journal-title":"Nat Commun"},{"key":"1430_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1161\/CIRCRESAHA.114.303312","volume":"114","author":"JS Knight","year":"2014","unstructured":"Knight JS, Luo W, O\u2019Dell AA, Yalavarthi S, Zhao W, Subramanian V, Guo C, Grenn RC, Thompson PR, Eitzman DT, Kaplan MJ. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res. 2014;114:947\u201356.","journal-title":"Circ Res"},{"key":"1430_CR33","doi-asserted-by":"publisher","first-page":"110487","DOI":"10.1016\/j.mce.2019.110487","volume":"494","author":"GK Dimitriadis","year":"2019","unstructured":"Dimitriadis GK, Nasiri-Ansari N, Agrogiannis G, Kostakis ID, Randeva MS, Nikiteas N, Patel VH, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Mol Cell Endocrinol. 2019;494:110487.","journal-title":"Mol Cell Endocrinol"},{"key":"1430_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","volume":"17","author":"\u039d Nasiri-Ansari","year":"2018","unstructured":"Nasiri-Ansari \u039d, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis ID, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17:106.","journal-title":"Cardiovasc Diabetol"},{"key":"1430_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","volume":"269","author":"F Gragnano","year":"2018","unstructured":"Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis. 2018;269:219\u201328.","journal-title":"Atherosclerosis"},{"key":"1430_CR36","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, Di Prospero NA, Eckel RH, Goldberg IJ. Mechanism of increased LDL (Low-Density Lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38:2207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1430_CR37","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3390\/ijms18081704","volume":"18","author":"Y Nakatsu","year":"2017","unstructured":"Nakatsu Y, Kokubo H, Bumdelger B, Yoshizumi M, Yamamotoya T, Matsunaga Y, Ueda K, Inoue Y, Inoue MK, Fujishiro M, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017;18:1704.","journal-title":"Int J Mol Sci"},{"key":"1430_CR38","doi-asserted-by":"publisher","first-page":"e0143396","DOI":"10.1371\/journal.pone.0143396","volume":"10","author":"M Terasaki","year":"2015","unstructured":"Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H, Watanabe T, Hirano T. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One. 2015;10:e0143396.","journal-title":"PLoS One"},{"key":"1430_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2017.01.018","volume":"11","author":"HE Bays","year":"2017","unstructured":"Bays HE, Sartipy P, Xu J, Sj\u00f6str\u00f6m CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol. 2017;11:450\u20138.e451.","journal-title":"J Clin Lipidol"},{"key":"1430_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome study. Diabetes Care. 2016;39:717\u201325.","journal-title":"Diabetes Care"},{"key":"1430_CR41","doi-asserted-by":"publisher","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11:e0165703.","journal-title":"PLoS One"},{"key":"1430_CR42","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1430_CR43","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, Kr\u00f6ller-Sch\u00f6n S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zin\u00dfius E, Agdauletova S, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9:e112394.","journal-title":"PLoS One"},{"key":"1430_CR44","doi-asserted-by":"publisher","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","volume":"875","author":"B Ganbaatar","year":"2020","unstructured":"Ganbaatar B, Fukuda D, Shinohara M, Yagi S, Kusunose K, Yamada H, Soeki T, Hirata KI, Sata M. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040.","journal-title":"Eur J Pharmacol"},{"key":"1430_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","volume":"276","author":"P Raggi","year":"2018","unstructured":"Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, Gupta M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98\u2013108.","journal-title":"Atherosclerosis"},{"key":"1430_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","volume":"124","author":"D Wolf","year":"2019","unstructured":"Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124:315\u201327.","journal-title":"Circ Res"},{"key":"1430_CR47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tcm.2019.01.004","volume":"29","author":"PK Shah","year":"2019","unstructured":"Shah PK. Inflammation, infection and atherosclerosis. Trends Cardiovasc Med. 2019;29:468\u201372.","journal-title":"Trends Cardiovasc Med"},{"key":"1430_CR48","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","volume":"39","author":"R Ortega","year":"2019","unstructured":"Ortega R, Collado A, Selles F, Gonzalez-Navarro H, Sanz MJ, Real JT, Piqueras L. SGLT-2 (Sodium-Glucose Cotransporter 2) inhibition reduces Ang II (Angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (Apolipoprotein E) knockout mice. Arterioscler Thromb Vasc Biol. 2019;39:1614\u201328.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1430_CR49","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.5551\/jat.52100","volume":"27","author":"A Rahadian","year":"2020","unstructured":"Rahadian A, Fukuda D, Salim HM, Yagi S, Kusunose K, Yamada H, Soeki T, Sata M. Canagliflozin prevents diabetes-induced vascular dysfunction in ApoE-deficient mice. J Atheroscler Thromb. 2020;27:1141\u201351.","journal-title":"J Atheroscler Thromb"},{"key":"1430_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/nep.12620","volume":"21","author":"RH Elliott","year":"2016","unstructured":"Elliott RH, Matthews VB, Rudnicka C, Schlaich MP. Is it time to think about the sodium glucose co-transporter 2 sympathetically? Nephrology (Carlton). 2016;21:286\u201394.","journal-title":"Nephrology (Carlton)"},{"key":"1430_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1479164117733626","volume":"15","author":"T Gaspari","year":"2018","unstructured":"Gaspari T, Spizzo I, Liu H, Hu Y, Simpson RW, Widdop RE, Dear AE. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15:64\u201373.","journal-title":"Diab Vasc Dis Res"},{"key":"1430_CR52","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1570161115666170201114835","volume":"15","author":"F Gragnano","year":"2017","unstructured":"Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, Diana V, Fimiani F, Limongelli G, Russo M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404\u201315.","journal-title":"Curr Vasc Pharmacol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-021-01430-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T08:20:36Z","timestamp":1670746836000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01430-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Review Board of Nanjing Drum Tower Hospital (No: 2019AE01062).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}